We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biomarkers Analyzed for Central Nervous System Lymphoma

By LabMedica International staff writers
Posted on 29 Oct 2019
Primary central nervous system lymphoma (PCNSL) is a rare type of extranodal non-Hodgkin lymphoma (NHL) accounting for 3% of all newly diagnosed primary intracranial tumors. More...
In patients presenting with focal brain lesions, fast and reliable diagnosis of PCNSL remains a challenge.

A proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF) are important factors in the pathophysiology, diagnosis, and prognosis of systemic B cell malignancies. However, their utility as biomarkers for the diagnosis of Central Nervous System Lymphoma (CNSL) and their effects on CNSL cells remain unclear.

Neurologists at the Ludwig Maximilians University (Munich, Germany) and their colleagues analyzed the levels of APRIL and BAFF in the cerebrospinal fluid (CSF) of 116 patients with suspected focal brain lesions, including 53 CNSL patients. Additionally, they serially measured their levels during chemotherapy and relapse. Furthermore, they analyzed the effect of APRIL and BAFF on two B cell lymphoma cell lines using proliferation, viability, and chemotaxis assays.

Enzyme-linked immunosorbent assay (ELISA) kits for APRIL were obtained from BioLegend and ELISA kits for BAFF were obtained from R&D Systems. Other methods used in the study included culturing cell lines, survival assays and chemotaxis assays where migrated cells were counted on a Gallios Flow Cytometer.

The scientists reported that CSF levels of APRIL and BAFF reliably differentiated CNSL from other focal brain lesions (including primary and metastatic brain tumors, autoimmune-inflammatory lesions, and neuroinfectious lesions) with a specificity of 93.7% (APRIL, BAFF) and a sensitivity of 62.3% (APRIL) and 47.1% (BAFF). Serial CSF analysis of CNSL patients during chemotherapy and relapse demonstrates a close correlation of APRIL CSF levels and the course of this disease. In vitro, APRIL and BAFF showed anti-apoptotic effects during methotrexate (MTX) treatment and mediated chemotaxis of malignant B cells.

The authors concluded that CSF levels of APRIL could help establishing the diagnosis of CNSL, especially if stereotactic biopsy is impossible or not conclusive. Moreover, APRIL can serve as a therapeutic marker during therapy and relapse. The study was published on October 15, 2019, in the Journal of Hematology & Oncology.

Related Links:
Ludwig Maximilians University


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.